



# Gennex Laboratories Limited

'AKASH GANGA' III Floor, Plot No.144 Srinagar Colony, Hyderabad – 500 073, TELANGANA (INDIA)  
Tel: +91-40-67334400 (30 lines) / 2374 6451, Fax: 67334433/01,  
Email: [info@gennexlab.com](mailto:info@gennexlab.com), [www.gennexlab.com](http://www.gennexlab.com)

Ref: GLL/OC/2019-20/0045

Date: 14/02/2020.

To  
Dy. General Manager,  
**BSE Ltd.,**  
Phiroje Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001.

To  
Asst. Manager (Listing)  
**The Ahmedabad Stock Exchange Ltd.,**  
Kamdhenu Complex, Opp.Sahajanand College,  
Ahmedabad – 380 015.

To  
The Secretary  
**The Calcutta Stock Exchange Association Ltd.,**  
7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

**Subject** : Submission of Standalone and Consolidated Un-Audited Limited Reviewed Financial Result as per Ind-As for the 3<sup>rd</sup> Quarter Ended 31<sup>st</sup> December, 2019.  
**Reference** : Security ID : GENNEX & Script Code – 531739

We enclose the Standalone and Consolidated Un-Audited Financial Results as per Ind-AS for the 3<sup>rd</sup> Quarter Ended 31<sup>st</sup> December, 2019 of the Company together with Limited Review Report thereon pursuant to the Regulation 33(3)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 which was approved and taken on records by the Board of Directors at its Meeting held today i.e., 14.02.2020.

The Board Meeting commenced at 04:30 p.m. and concluded at 06:00 p.m.

We would be obliged if you could take the above on records.

Thanking You,

Yours faithfully,  
For Gennex Laboratories Ltd.,

Authorised Signatory

Encl: as above



**GENNEX LABORATORIES LIMITED**  
 REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, SANGAREDDY DIST - 502 325  
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2018  
 Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com  
 CIN: L24230TG1990PLC011168

PART - I							
Statement of standalone Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2019							
						(Rs. in lakhs)	
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Income from Operations</b>						
	(a) Revenue from Operations	1468.08	1339.60	1521.55	4416.41	3544.20	5580.27
	(b) Other operating Income	22.66	20.24	20.52	77.08	53.22	78.25
	<b>Total Income from operations (net)</b>	<b>1490.74</b>	<b>1359.84</b>	<b>1542.07</b>	<b>4493.49</b>	<b>3597.42</b>	<b>5658.52</b>
2	<b>Expenses</b>						
	(a) Cost of material consumed	912.07	832.33	939.82	2774.47	2254.89	3468.05
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	2.93	40.52
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-10.17	-62.02	-34.60	-169.74	-220.30	-238.82
	(d) Employee benefit expense	193.19	163.21	167.93	526.53	431.42	612.20
	(f) Finance Cost	16.91	17.65	25.65	59.98	59.09	98.47
	(g) Depreciation and amortisation expense	30.51	28.04	30.51	81.47	79.01	79.38
	(h) Other expenses	314.36	316.69	330.83	1016.23	812.93	1296.00
	<b>Total expenses</b>	<b>1456.87</b>	<b>1295.90</b>	<b>1460.14</b>	<b>4288.94</b>	<b>3419.97</b>	<b>5355.80</b>
3	<b>Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)</b>	<b>33.87</b>	<b>63.94</b>	<b>81.93</b>	<b>204.55</b>	<b>177.45</b>	<b>302.72</b>
4	Exceptional items	0.00	10.86	0	10.86	0.00	0.00
5	<b>Profit(+)/Loss(-) before tax (3+4)</b>	<b>33.87</b>	<b>74.80</b>	<b>81.93</b>	<b>215.41</b>	<b>177.45</b>	<b>302.72</b>
6	Taxes of earlier years	0.00	0.00	0.00	0.00	0.00	-0.15
7	Current Tax	-14.00	-19.00	0.00	-60.00	0.00	-85.00
8	Deferred tax(benefit/expense)						4.51
9	<b>Total Tax expense</b>	<b>-14.00</b>	<b>-19.00</b>	<b>0.00</b>	<b>-60.00</b>	<b>0.00</b>	<b>-80.64</b>
10	Net movement in regulatory deferral account balances related to Profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11	<b>Profit(+)/Loss(-) for the period from continuing operation (5-9)</b>	<b>19.87</b>	<b>55.80</b>	<b>81.93</b>	<b>155.41</b>	<b>177.45</b>	<b>222.08</b>
12	Profit(+)/Loss(-) from discontinued operations before tax						
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	<b>Net Profit(loss) for the period from discontinued operations</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
16	<b>Total profit(loss) for period</b>	<b>19.87</b>	<b>55.80</b>	<b>81.93</b>	<b>155.41</b>	<b>177.45</b>	<b>222.08</b>
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	0
18	<b>Net profit(loss) for period</b>	<b>19.87</b>	<b>55.80</b>	<b>81.93</b>	<b>155.41</b>	<b>177.45</b>	<b>222.08</b>
19	<b>Paid-up Equity Share Capital</b> (Face value Rs. 1 each Equity Share) Other Equity	<b>1265.03</b>	<b>1265.03</b>	<b>1265.03</b>	<b>1265.03</b>	<b>1265.03</b>	<b>1265.03</b> <b>2134.74</b>
20	<b>Earning Per Equity Share (EPS) (Face value of Rs 1 per Share)</b> ( of Rs. 1 each ) (not annualised) :						
	(a) Basic	0.016	0.044	0.065	0.123	0.140	0.176
	(b) Diluted	0.016	0.044	0.065	0.123	0.140	0.176

**Notes to the results:**

- 1) The above audited financial results have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on Feb 14, 2020.
- 2) The statement has been prepared in accordance with Companies ( Indian Accounting Standard) Rules, 2015 (IndAS) prescribed under section 133 of Companies Act, 2013 and other prescribed accounting practices and policies to the extent possible.
- 3) The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Operating Segment and believes that the Company has only one reportable segment namely " Bulk Drugs,Biotech Products and Intermediates".
- 4) Provision for IAS-12 Deferred Tax will be made at the end of the year.
- 5) Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.
- 6) The Figures for the Quarter ended 31-March-2019 and the corresponding quarter ended in the Previous year, as reported in these financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to data figures upto the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subject to audit. Previously period/year figures have

For and on behalf of the Board  
 For Gennex Laboratories Limited  
 sd/-  
 Arihant Baid  
 Managing Director

Place: Hyderabad  
 Date: 14.02.2020

**INDEPENDENT AUDITOR'S REVIEW REPORT ON  
REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS**

To  
The Board of Directors,  
**GENNEX LABORATORIES LIMITED**

We have reviewed the accompanying statement of standalone unaudited financial results of **GENNEX LABORATORIES LIMITED** ("the Company") for the Quarter Ended 31st December, 2019 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement

Place : Hyderabad  
Date : 14<sup>th</sup> February, 2020  
UDIN: 20205140AAAAC91015



**For PPKG & CO**  
Chartered Accountants  
FRN No. 009655S

*Girdhari Lal Toshniwal*

**GIRDHARI LAL TOSHNIWAL**  
(Partner)  
M. No. 205140



**GENNEX LABORATORIES LIMITED**  
 REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, SANGAREDDY DIST - 502 325  
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2018  
 Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com  
 CIN: L24230TG1990PLC011168

PART - I							
Statement of Consolidated Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2019							
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2019 (Unaudited)	30.09.2019 (Unaudited)	31.12.2018 (Unaudited)	31.12.2019 (Unaudited)	31.12.2018 (Unaudited)	31.03.2019 (Audited)
1	<b>Income from Operations</b>						
	(a) Revenue from Operations	1468.08	1339.60	1521.55	4416.41	3544.20	5580.27
	(b) Other operating Income	22.66	20.24	20.52	77.08	53.22	78.25
	<b>Total Income from operations (net)</b>	<b>1490.74</b>	<b>1359.84</b>	<b>1542.07</b>	<b>4493.49</b>	<b>3597.42</b>	<b>5658.52</b>
2	<b>Expenses</b>						
	(a) Cost of material consumed	912.07	832.33	939.82	2774.47	2254.89	3468.05
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	2.93	40.52
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-10.17	-62.02	-34.60	-169.74	-220.30	-238.82
	(d) Employee benefit expense	193.19	163.21	167.93	526.53	431.42	612.20
	(f) Finance Cost	16.91	17.65	25.65	59.98	59.09	98.47
	(g) Depreciation and amortisation expense	30.51	28.04	30.51	81.47	79.01	79.38
	(h) Other expenses	314.36	316.69	330.83	1016.23	812.93	1296.00
	<b>Total expenses</b>	<b>1456.87</b>	<b>1295.90</b>	<b>1460.14</b>	<b>4288.94</b>	<b>3419.97</b>	<b>5355.80</b>
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	33.87	63.94	81.93	204.55	177.45	302.72
4	Exceptional items	0.00	10.86	0	10.86	0.00	0.00
5	Profit(+)/Loss(-) before tax (3+4)	33.87	74.80	81.93	215.41	177.45	302.72
6	Taxes of earlier years	0.00	0.00	0.00	0.00	0.00	-0.15
7	Current Tax	-14.00	-19.00	0.00	-60.00	0.00	-85.00
8	Deferred tax(benefit/expense)						4.51
9	<b>Total Tax expense</b>	<b>-14.00</b>	<b>-19.00</b>	<b>0.00</b>	<b>-60.00</b>	<b>0.00</b>	<b>-80.64</b>
10	Net movement in regulatory deferral account balances related to Profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11	<b>Profit(+)/Loss(-) for the period from continuing operation (5-9)</b>	<b>19.87</b>	<b>55.80</b>	<b>81.93</b>	<b>155.41</b>	<b>177.45</b>	<b>222.08</b>
12	Profit(+)/Loss(-) from discontinued operations before tax	0.0	0.0	0.0	0.0	0.0	0.0
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	<b>Net Profit(loss) for the period from discontinued operations</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	-1.09	-2.10	0.0	-4.03	0.0	-8.08
16	<b>Total profit(loss) for period</b>	<b>18.78</b>	<b>53.70</b>	<b>81.93</b>	<b>151.38</b>	<b>177.45</b>	<b>214.00</b>
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	0
18	<b>Net profit(loss) for period</b>	<b>18.78</b>	<b>53.70</b>	<b>81.93</b>	<b>151.38</b>	<b>177.45</b>	<b>214.00</b>
19	<b>Paid-up Equity Share Capital</b> (Face value Rs. 1 each Equity Share)	<b>1265.03</b>	<b>1265.03</b>	<b>1265.03</b>	<b>1265.03</b>	<b>1265.03</b>	<b>1265.03</b>
	<b>Other Equity</b>						<b>2134.74</b>
20	<b>Earning Per Equity Share (EPS) (Face value of Rs 1 per Share)</b> ( of Rs. 1 each ) (not annualised) :						
	(a) Basic	0.015	0.042	0.065	0.120	0.140	0.169
	(b) Diluted	0.015	0.042	0.065	0.120	0.140	0.169

Notes to the results:

- The above audited financial results have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on Feb 14, 2020.
- The statement has been prepared in accordance with Companies ( Indian Accounting Standard) Rules, 2015 (IndAS) prescribed under section 133 of Companies Act, 2013 and other prescribed accounting practices and policies to the extent possible.
- The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Operating Segment and believes that the Company has only one reportable segment namely " Bulk Drugs,Biotech Products and Intermediates".
- Provision for IAS-12 Deferred Tax will be made at the end of the year.
- Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.
- The Figures for the Quarter ended 31-March-2019 and the corresponding quarter ended in the Previous year, as reported in these financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to data figures upto the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subject to audit. Previously period/year figures have

For and on behalf of the Board  
 For Gennex Laboratories Limited  
 sd/-  
 Arihant Baid  
 Managing Director

Place: Hyderabad  
 Date: 14.02.2020



**INDEPENDENT AUDITOR'S REVIEW REPORT ON  
REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS**

To  
The Board of Directors,  
**GENNEX LABORATORIES LIMITED**

We have reviewed the accompanying statement of Consolidated unaudited financial results of **GENNEX LABORATORIES LIMITED** ("the Company") for the Quarter Ended 31st December, 2019 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement

Place : Hyderabad  
Date : 14<sup>th</sup> February, 2020  
UDIN : 20205140 AAAACH8448



**For PPKG & CO**  
Chartered Accountants  
FRN No. 009655S

*Girdhari Lal Toshniwal*  
**GIRDHARI LAL TOSHWAL**  
(Partner)  
M. No. 205140